IP Verse

Theravance Biopharma R&D Ip, Llc V. Lupin Inc. - 1:23-cv-00187

Explore the details of the Theravance Biopharma R&D Ip, Llc V. Lupin Inc. case under case number 1:23-cv-00187 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00187
Filing Date
Feb 17, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved in the Case

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Theravance Biopharma R&D IP, LLC -
Lupin Inc. -

Patents Involved in the Case

This case involves 5 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US8541451B2
-US9765028B2
-US11008289B2
-US10550081B2
-US11484531B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Feb 17, 2023Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Theravance Biopharma, Inc. for Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, and Theravance Biopharma US, Inc. filed by Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc.. (mpb) (Entered: 02/21/2023)PACER Document
Feb 17, 2023Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,541,451; 9,765,028; 10,550,081; 11,008,289; 11,484,531. (mpb) (Entered: 02/21/2023)PACER Document
Feb 17, 2023Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/12/2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 5/9/2026. (mpb) (Entered: 02/21/2023)PACER Document
Feb 17, 2023Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 02/21/2023)PACER Document
Feb 17, 2023COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023)PACER Document
Feb 21, 2023Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Viatris, Inc. for Mylan Ireland Limited, Mylan Specialty L.P. filed by Mylan Ireland Limited, Mylan Specialty L.P.. (Stamoulis, Stamatios) (Entered: 02/21/2023)PACER Document
Feb 17, 2023DEFICIENCY NOTICE issued by the Court to Plaintiffs Mylan Ireland Limited and Mylan Specialty L.P.: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (mpb)PACER Document
Feb 17, 2023No Summons Issued. (mpb)PACER Document
Mar 28, 2023NOTICE of Voluntary Dismissal by Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc. (Bourke, Mary) (Entered: 03/28/2023)PACER Document
Mar 28, 2023Report to the Commissioner of Patents and Trademarks. (ntl) (Entered: 03/28/2023)PACER Document
Feb 22, 2023Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (rjb)PACER Document
Mar 28, 2023CASE CLOSED (ntl)PACER Document